3SOF

Quote from: Melf Elf on February 14, 2007, 04:54:23 AM
Hold at 1.75, and GET THE JOB DONE!  We want to see 1.79 get printed today.

1.75 got broken right at the open of 1.74, then a print of 1.73. 

Most of the day was spent trying to hang onto 1.75, but went down and closed near the low of the day, so this particular Symmetrical Triangle possibility has failed.

http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/02/18/nflu18.xml

nice news, but still traded @ 1.72$ 

Generex Biotechnology Expands Glucose RapidSpray(TM) Distribution
Tuesday February 20, 10:07 am ET

TORONTO--(MARKET WIRE)--Feb 20, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced expanded distribution of Glucose RapidSpray, the Company's proprietary buccal glucose spray product. The product is now available in over 2,500 stores in the United States at Aurora Pharmacy, Inc., Bi-Mart Corporation, The Diabetes Place, Fruth Pharmacy, Inc., Hy-Vee, Inc., Kerr Drug, Inc., The Medicine Shoppe® Pharmacy, Meijer, Inc., and ShopKo Stores. The product is also available for purchase online at GlucoseRapidSpray.com and DiabeticExpress.com.

Glucose RapidSpray is an innovative alternative for people who want additional glucose in their diet. Glucose RapidSpray delivers a fat-free, low-calorie glucose formulation developed using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray delivers glucose directly into the buccal cavity. Glucose RapidSpray is simple to carry and use.

Accumulation$

March 13, 2007 - 7:00 AM EDT           

 
GNBT 1.68   0.00 

 
Generex Biotechnology Granted Patents in Canada and Europe
Company Expands Drug Delivery Platform Patent Portfolio in Canada and Europe
Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has expanded its patent coverage with newly issued patents in Canada and Europe issued by the Canadian Intellectual Property Office and the European Patent office, respectively.

The Canadian patent titled "Pharmaceuticals Solubilized in Aerosol Propellant" relates to a formulation with a pharmaceutical agent solubilized in a propellant which can be administered buccally or into the lungs using a metered dose spray applicator.

The European patent titled "Pulmonary Drug Delivery" relates to an improved delivery system for the administration of large-molecule pharmaceuticals such as peptidic drugs, vaccines, and hormones, which may be administered by means of an aerosol into the mouth for buccal or pulmonary applications. The patent will take effect in several European countries including Germany, France, and the United Kingdom.

The Company currently holds an aggregate of 82 patents worldwide (20 of which are United States Patents) and has an aggregate of 60 patent applications pending in various jurisdictions.

Saudi Arabia reports bird flu outbreak
23 Mar 2007 06:33:39 GMT
Source: Reuters
Alert Me | Printable view | Email this article | RSS  [-] Text

• 
  Background
  Bird flu
  More  RIYADH, March 23 (Reuters) - Saudi Arabia's agriculture ministry has said the deadly H5N1 strain of bird flu had been discovered in birds at a house in the east of the kingdom, the official news agency SPA reported.
  
  It said in a report late on Thursday the virus was found in peacocks, turkeys, ostriches and parrots at the house last month after a man phoned the ministry about deaths of birds.
  
  All birds in the area had been culled, SPA said.
  
  No further details were immediately available.
  
  The last reported cases of bird flu in Saudi Arabia involved 37 falcons in 2006.
  
  Last month, Saudi Arabia lifted bans going back to 2004 on poultry imports from 42 countries.
  
  The H5N1 virus has killed 169 people worldwide since 2003, according to the World Health Organisation. Health experts fear the virus could mutate into a form that passes easily from human to human, unleashing a pandemic that could kill millions.

News, maybe this can get GNBT running a bit like NVAX lately (I am buying some shares here at 1.64 to see where it goes):

TORONTO -- (MARKET WIRE) -- 04/20/07 --

   Generex Biotechnology Corporation (NASDAQ: GNBT), the leader in drug
delivery for metabolic diseases through the inner lining of the mouth,
announced today that it has expanded its patent portfolio with newly issued
patents in Canada and Mexico issued by the Canadian Intellectual Property
Office and the Mexican Institute of Intellectual Property, respectively.

  The Canadian patent titled "Pulmonary Drug Delivery" contains claims to an
aerosol pharmaceutical formulation, metered dose dispenser, and use thereof.
The patent discloses an improved delivery system for the administration of
large molecule pharmaceuticals which can be administered by means of an aerosol
into the mouth for buccal or pulmonary application.

  The Mexican patent titled "Micellar Pharmaceutical Compositions for Buccal
and Pulmonary Application" is an extant United States Patent held by the
Company containing claims to pharmaceutical compositions comprising a
macromolecular pharmaceutical agent in mixed micellar form.  The patent also
discloses methods for making and using the pharmaceutical compositions.

  "We welcome the expansion of our intellectual property protection in North
America as the Company moves forward on its clinical and regulatory path inthe
major markets," said Rose C. Perri, the Company's Chief Operating Officer. "The
addition of a new Mexican patent is significant as this market will prove
valuable for our flagship product Generex Oral-lyn (TM) and future indications
utilizing the RapidMist(TM) platform."

  The Company currently holds an aggregate of 84 patents worldwide (20 of which
are United States Patents) and has an aggregate of 58 patent applications
pending in various jurisdictions.

  About Generex

  Generex is engaged in the research and development of drug delivery
systemsand technologies.  Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral
cavity (with no deposit in the lungs).  The Company's proprietary liquid
formulations allow drugs typically administered by injection to be absorbed
into the body by the lining of the inner mouth using the Company's proprietary
RapidMist(TM) device.  The Company's flagship product, oral insulin (Generex
Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of
patients with Type-1 and Type-2 diabetes, is in various stages of clinical
trials around the world.  For more information, visit the Generex website at
www.generex.com.

  Safe Harbor Statement: This release and oral statements made from time to
time by Generex representatives concerning the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995.  These statements can be identified by
introductory words such as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects" or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities,
clinical studies, regulatory submissions and approvals, and similar operating
matters.  Many factors may cause actual results to differ from forward-looking
statements,including inaccurate assumptions and a broad variety of risks and
uncertainties, some of which are known and others of which are not. Known risks
and uncertainties include those identified from time to time in the reports
filed by Generex   with the Securities and Exchange Commission, which should be
considered together with any forward-looking statement. No forward-looking
statement is a guarantee of future results or events, and one should avoid
placing undue reliance on such statements.  Generex cannot be sure when or if
it will be permitted by regulatory agencies to undertake additional clinical
trials or to commence any particular phase of clinical trials.  Because of
this, statements regarding the expected timing of clinical trials cannot be
regarded as actual predictions of when Generex will obtain regulatory approval
for any "phase" of clinical trials. Generex claims the protection of the safe
harbor for forward-lookingstatements that is contained in the Private
Securities Litigation Reform Act.

     For more information, please contact: For Generex: Shayne Gilliatt Generex
800-391-6755 416-364-2551 Andrew Hellman CEOcast, Inc. 212-732-4300

  (END) Dow Jones Newswires

  04-20-07 0945ET

09:45 042007

GNBT has been declining with low volume as a SHELF was filed last December (no shares have been offered) and the company prepares for a Phase III trial of Oral-lyn.  I have posted the results (as seen in presentation abstracts) of two Phase II trials of Oral-lyn on the digitaltradz.com board.  (I post a lot of finds there that relate to GNBT.) I believe that the results will be properly PR'd at the Amer Diab sessions late June.  The CEO told me that last Oct, and it still appears to be the plan.  Now we know Oral-lyn works, as the one study shows a superior effectt when compared to injections.   Both show a lowering of HBA1c levels that are comparable, or superior, to injectable insulin.  The 100 day study has the final levels of the Oral-lyn group down to 6.1.  That's really good.    

Recent comments by the CEO are of interest.  In the R & R webcast last week, Ms Gluskin spelled out plans for an upcoming 35 center Phase III trial that will be worldwide.  We din't realize the scope of the upcoming trial and I found that to be very good news.  Also, Phase IV trials are being planned in L America and the Miidle East where the Ecuadrian dossier for Oral-lyn approval is accepted and only these marketing trials required.  These comments were made May 11th 2007 on an online interview with CEOCast.  

Last week at an R & R webcast event in Monaco Ms Gluskin made other statements regarding the 35 center worldwide trial and perhaps enlightening remarks about Cardinal/Blackstone Venture.  Cardinal Health has been making Phase III batches of Oral-lyn as per the clinical trials manufacturing agreement of June 2006.  The agreement was further ammended and signed in feb 2007- as per SEC filings.  Cardinal divested this "PTC" contract manufacturing division to Blackstone recently.  **(Blackstone themselves may have an IPO soon.)**  Cardinal/Blackstone has not only paid for the Oral-lyn filling equipment needed to fill the product as per the trial agreement, but expanded the equipment investment to allow for the filling of 25 million units per year.  That's a heck of a lot of Oral-lyn for a trial of 250 to 500 patients!  Ms Gluskin, at the webcast event, stated that the cost is ZERO to Generex.  Something is doing here with Cardinal/Blackstone.  Just a guess on why this big investment for a small deal.  Ms Gluskin said it is a possibility when explaining the realtionship.  Perhaps contract manufacturing amnd distribution rights post US and Canadian approval.  Ms Gluskin said it is a possibility when explaining the relationship.  I see that this Cardinal/Blackstone contract manufacturingdivision currently offers nasal, inhalable, and oral pill delivery choices to the biotechs and Pharmas it serves.  Did they just purchase the equipment to add buccal cavity?  Keep an eye on any developments and tuck the thought away.

I've been long on GNBT for a long while.  Just building a position and waiting as these trials and the regulatory process is long and drawn out.  That's why this sector requires the most patience for a LONG and many bail out.  Understandable.  But the SHM is May 29th.  The ADA sessions are June 29th.  Keep your eyes on GNBT, because we all know the biggest gains in biotechs are during the Phase III process.  Guess I'm locked and loaded.  

You chart readers can find good entry spots, but just keep your eyes open.  jmo

rjs9787      

GNBT up at least 32% above the open

Ares, GNBT shot up over 42% with the press release:

http://biz.yahoo.com/iw/070612/0265144.html

"Rodman and Renshaw Initiates Coverage of Generex Biotechnology With Market Outperform Rating and $6.00 Price Target ..."
Tuesday June 12, 10:17 am ET

Thanks Livelife,

It also bounced off a key support.
Someone knows how to time the news.

Ares

Nice close above the 200sma on above than average volume with the MACD and oversold Stochastics crossing up on stockcharts.

Looking forward to the analyst's projection.

Quote from: LiveLife on June 12, 2007, 05:15:52 PM
Ares, GNBT shot up over 42% with the press release:

http://biz.yahoo.com/iw/070612/0265144.html

"Rodman and Renshaw Initiates Coverage of Generex Biotechnology With Market Outperform Rating and $6.00 Price Target ..."
Tuesday June 12, 10:17 am ET

Ares, now the question is - with today's HUGE gain, GNBT will temporarily be UNTRENDABLE.  Will profit taking occur Wednesday?

Hi Livelife,

We'll have to wait and see what the market will decide to do tomorrow.
A lot of times, a stock still goes up even with overbought conditions.
Just like what happened with PRXI recently, a stock that I was watching too.
What we have now is a fresh cross of the MACD and a fresh cross of an oversold slow stochastics on GNBT.
Probality is more on the long side on this stock now.

As far as resistance is concerned, today's price wicked on the descending trendline of the daily chart.
Would there be enough demand to push through that?
We shall see...
It would be nice to see decreasing volume as price goes down,  if traders decide to take profits first.
Who knows (may be the AX), it may gap up too.
It would be interesting to watch how this stock will perform in the coming days.

Just like the weather, we could only forecast with our indicators.

Thank you again for introducing me to 3SOF (for I've learned a lot since we met at the yahoo board few years back). Too bad, I didn't check it out right away.

It's amazing how the more that we know, the more we know what we don't know.

Happy trading.

Ares

GNBT new daily high.